Navigation
The Company
Our Science
mTOR Pathway
nab
Technology Platform
Publications and Abstracts
Our Medicine
Our Medicine
Advanced Malignant PEComa
Pipeline
Expanded Access
Patients
Overview
Patient Advocacy
Contact Us
General Contact
For Healthcare Professionals
Careers
cache
Home
cache
Next Post
Previous Post
cache
David Dornan, PhD
January 1, 2020
/
Uncategorized
Like
this post!
Share
the Post
About
the Author
Related
Posts
Mohammad Hirmand, MD
Aadi Bioscience Initiates Rolling Submission of NDA to FDA for nab-sirolimus (ABI-009, FYARRO™) for the Treatment of Advanced Malignant PEComa
nab
-Sirolimus for Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in
TSC1
and
TSC2
in a Phase 2, Multicenter, Open-label Tumor-Agnostic Trial: PRECISION 1
cache
Improved tumor penetration, anti-tumor activity, and survival of ABI-009 (
nab
-sirolimus) versus oral rapamycin and everolimus and investigation of mTOR pathway inhibition
Phase 2, multicenter, open-label basket trial of
nab
-sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in
TSC1
or
TSC2
genes (PRECISION I)
A Phase 2, open-label, single-arm, prospective, multicenter study of
nab
-sirolimus plus letrozole in advanced or recurrent endometrioid endometrial cancer
Read More
Karin Hehenberger, MD, PhD
Comments
Comments are closed.
Next Post
Previous Post
Comments
Comments are closed.